Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1989 1
1990 1
1991 1
1992 1
1995 1
1996 2
1997 1
1998 2
1999 3
2000 5
2001 8
2002 13
2003 12
2004 7
2005 9
2006 4
2007 6
2008 5
2009 5
2010 9
2011 9
2012 7
2013 4
2014 2
2015 7
2016 2
2017 1
2019 1
2021 1
2022 1
2023 3
2024 3
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial.
Baker LD, Espeland MA, Whitmer RA, Snyder HM, Leng X, Lovato L, Papp KV, Yu M, Kivipelto M, Alexander AS, Antkowiak S, Cleveland M, Day C, Elbein R, Tomaszewski Farias S, Felton D, Garcia KR, Gitelman DR, Graef S, Howard M, Katula J, Lambert K, Matongo O, McDonald AM, Pavlik V, Raman R, Salloway S, Tangney C, Ventrelle J, Wilmoth S, Willliams BJ, Wing R, Woolard N, Carrillo MC. Baker LD, et al. Among authors: gitelman dr. JAMA. 2025 Aug 26;334(8):681-691. doi: 10.1001/jama.2025.12923. JAMA. 2025. PMID: 40720610 Clinical Trial.
Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER).
Baker LD, Snyder HM, Espeland MA, Whitmer RA, Kivipelto M, Woolard N, Katula J, Papp KV, Ventrelle J, Graef S, Hill MA, Rushing S, Spell J, Lovato L, Felton D, Williams BJ, Ghadimi Nouran M, Raman R, Ngandu T, Solomon A, Wilmoth S, Cleveland ML, Williamson JD, Lambert KL, Tomaszewski Farias S, Day CE, Tangney CC, Gitelman DR, Matongo O, Reynolds T, Pavlik VN, Yu MM, Alexander AS, Elbein R, McDonald AM, Salloway S, Wing RR, Antkowiak S, Morris MC, Carrillo MC; U.S. POINTER Study Group. Baker LD, et al. Among authors: gitelman dr. Alzheimers Dement. 2024 Feb;20(2):769-782. doi: 10.1002/alz.13365. Epub 2023 Sep 30. Alzheimers Dement. 2024. PMID: 37776210 Free PMC article. Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition.
Harrison TM, Ward T, Taggett J, Maillard P, Lockhart SN, Jung Y, Lovato LC, Koeppe R, Jagust WJ, Harvey D, Masdeu JC, Oh H, Gitelman DR, Aggarwal NT, Espeland MA, Cleveland ML, Whitmer R, Farias ST, Salloway S, Pavlik V, Yu M, Tangney C, Snyder H, Carrillo M, Baker LD, Vemuri P, DeCarli C, Landau SM; U.S. POINTER Study Group. Harrison TM, et al. Among authors: gitelman dr. Alzheimers Dement. 2025 Jan;21(1):e14399. doi: 10.1002/alz.14399. Epub 2024 Dec 6. Alzheimers Dement. 2025. PMID: 39641363 Free PMC article.
System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment.
Snider BJ, Biffi A, Bozeat S, Clevenger C, Farrar G, Gitelman D, Kolster R, Mattke S, Mielke M, Mukherjee D, Murphy J, Okhravi H, Rabinovici GD, Rentz D, Soria J, Synder H, Walker G, Mahinrad S, Carrillo MC, Weber CJ. Snider BJ, et al. Among authors: gitelman d. Alzheimers Dement (N Y). 2025 Jun 19;11(2):e70094. doi: 10.1002/trc2.70094. eCollection 2025 Apr-Jun. Alzheimers Dement (N Y). 2025. PMID: 40547330 Free PMC article.
Neural Connectivity in Syntactic Movement Processing.
Europa E, Gitelman DR, Kiran S, Thompson CK. Europa E, et al. Among authors: gitelman dr. Front Hum Neurosci. 2019 Feb 13;13:27. doi: 10.3389/fnhum.2019.00027. eCollection 2019. Front Hum Neurosci. 2019. PMID: 30814941 Free PMC article.
Attention and its disorders.
Gitelman DR. Gitelman DR. Br Med Bull. 2003;65:21-34. doi: 10.1093/bmb/65.1.21. Br Med Bull. 2003. PMID: 12697614 Review.
Baseline characteristics of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER): Successful enrollment of a diverse clinical trial cohort at risk for cognitive decline.
Whitmer RA, Baker LD, Carrillo MC, Snyder HM, Cleveland ML, Gitelman DR, Kivipelto M, Leng XI, Lovato L, Papp KV, Pavlik VN, Salloway SP, Tangney CC, Farias ST, Williamson JD, Wilmoth S, Woolard N, Yu M, Espeland MA; U.S. POINTER Study Group. Whitmer RA, et al. Among authors: gitelman dr. Alzheimers Dement. 2025 Jun;21(6):e70351. doi: 10.1002/alz.70351. Alzheimers Dement. 2025. PMID: 40556311 Free PMC article. Clinical Trial.
131 results